Compare Gilead Sciences, Inc. (GILD) vs GameStop Corp. (GME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs GameStop Corp. — how do they compare? Gilead Sciences, Inc. trades at $136.31 (market cap $168.35B), while GameStop Corp. trades at $18.53 (market cap $8.44B). The key difference: Gilead Sciences, Inc. is far larger — about 19.9× GameStop Corp.'s market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals.
| GILD | GME | |
|---|---|---|
Market Cap | $168.35B | $8.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $27.69 |
52-Week Low | $110.56 | $18.79 |
Enterprise Value | $191.42B | $4.42B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
GME trades at $18.605, down 0.98% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 beating expectations of $0.16. Revenue for 2025 was $3.82B, with net income of $131.3M and a profit margin of 3.43%. Recent news highlights a potential shift from a $56B eBay takeover bid to a partnership, as reported by Bloomberg on August 10, 2026.
The outlook is mixed: strong profitability improvements and debt reduction support upside, but analyst consensus is cautious with only 16.67% buy ratings. Key risks include execution of strategic partnerships, competitive pressures in retail, and shareholder dilution from recent debt-for-stock swaps. The stock's valuation appears reasonable with a P/E of 14.04, but sentiment remains divided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
